Breaking News
Get 40% Off 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Apellis Pharmaceuticals Inc (APLS)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Apellis Pharma's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
49.86 +1.93    +4.03%
26/04 - Closed. Currency in USD ( Disclaimer )
After Hours
51.25
+1.39
+2.79%
0:59:16 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 959,886
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 48.85 - 50.98
Apellis Pharma 49.86 +1.93 +4.03%

Apellis Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of Apellis Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

767

Equity Type

ORD

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Contact Information

Address 100 Fifth Avenue
Waltham, 02451
United States
Phone 617 977 5700
Fax -

Top Executives

Name Age Since Title
Lokchung Chan 70 2013 Independent Chairman of the Board
Cedric Francois 49 2009 Co-Founder, President, CEO & Director
Stephanie Monaghan O’Brien 64 2013 Independent Director
Alec Machiels 50 2009 Co-Founder & Director
Jason Scott Slakter 65 2015 Member of AMD Scientific Advisory Board
Gabriel J. Coscas - 2015 Member of AMD Scientific Advisory Board
Marsha Wills-Karp - - Member of Pulmonology Scientific Advisory Board
Paul R. Fonteyne 62 2020 Independent Director
A. Sinclair Dunlop 51 2010 Independent Director
Claudia Kemper - 2015 Member of Pulmonology, AMD & PNH Scientific Advisory Board
Robert A. Brodsky - 2015 Member of PNH Scientific Advisory Board
Johanna M. Seddon - 2015 Member of AMD Scientific Advisory Board
Susan M. Lea - 2015 Member of Pulmonology, AMD & PNH Scientific Advisory Board
Philip J. Rosenfeld - 2015 Member of AMD Scientific Advisory Board
Bruno Crestani - 2015 Member of Pulmonology Scientific Advisory Board
Toby Maher - 2015 Member of Pulmonology Scientific Advisory Board
Janet Stoltz Sunness - 2015 Member of AMD Scientific Advisory Board
Michael Yeadon - 2015 Member of Pulmonology Scientific Advisory Board
Carl Atkinson - 2015 Member of Pulmonology Scientific Advisory Board
Jaroslaw Maciejewski - 2015 Member of PNH Scientific Advisory Board
Peter Hillmen - 2015 Head of Hematology Engagement & Member of PNH Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

APLS Comments

Write your thoughts about Apellis Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email